Can I read Current Opinion on the Pharmacogenomics of Paclitaxel-induced Toxicity on EtoBox?

Current Opinion on the Pharmacogenomics of Paclitaxel-induced Toxicity by Zeina N. Al-Mahayri; Mohammad M. AlAhmad; Bassam R. Ali is a Medicine article available to read on EtoBox.

What is Current Opinion on the Pharmacogenomics of Paclitaxel-induced Toxicity about?

Introduction: Paclitaxel is a microtubule stabilizer that is currently one of the most utilized chemotherapeutic agents. Its efficacy in breast, uterine, lung and other neoplasms made its safety profile enhancement a subject of great interest. Neurotoxicity is the most common paclitaxel-associated toxicities. In addition, hypersensitivity reactions, hematological, gastrointestinal, and cardiac toxicities are all encountered. Areas covered: The current review explores paclitaxel-induced toxicities mechanisms and risk factors. Studies investigating these toxicities pharmacogenomic biomarkers are reviewed and summarized. There is a limited margin of consistency between the retrieved associations. Variants in genes related to neuro-sensitivity are the most promising candidates for future studies. Expert opinion: Genome-wide association studies highlighted multiple-candidate biomarkers relevant to neuro-sensitivity. Most of the identified paclitaxel-neurotoxicity candidate genes are derived from congenital neuropathy and diabetic-induced neurotoxicity pathways. Future studies should explore these sets of genes while considering the multifactorial nature of paclitaxel-induced neurotoxici

Who reads Current Opinion on the Pharmacogenomics of Paclitaxel-induced Toxicity?

Author

Zeina N. Al-Mahayri; Mohammad M. AlAhmad; Bassam R. Ali

Publisher

Informa UK Limited

Published

2021

Language

EN

Field

Medicine (Health Sciences)